Supervivencia de pacientes con cáncer de pulmón no microcítico tratados con docetaxel en segunda línea
Resumen
Introducción: El cáncer de pulmón es la primera causa de muerte por cáncer. El 85% de los pacientes presentan cáncer de pulmón de células no pequeñas, más de un 50% se diagnostican en etapas avanzadas donde el pilar terapéutico es el tratamiento sistémico. Con quimioterapia convencional, al año de diagnóstico están vivos aproximadamente el 33%, y en el escenario de recaída y/o progresión la quimioterapia con Docetaxel es una opción válida de tratamiento.
Metodología: Se realizó un estudio descriptivo, retrospectivo con el objetivo de describir a los pacientes con CPCNP tratados con docetaxel en segunda línea en el INOR de enero de 2018 a diciembre de 2020. Se describieron las características clínicas, patológicas, así como la terapéutica recibida y sus resultados. Se relacionó la supervivencia con variables clínicas
Resultados: Fueron analizados 82 pacientes. El 58.5% fue de sexo masculino, el 43.9% tenían entre 60-69 años. La histología que predominó fue el Adenocarcinoma (48.1%). La etapa IV al diagnóstico fue la más frecuente (41.5%). El 67.1% presentaban ECOG 1 en la recaía y/o progresión. El 65.9% cumplieron el estándar terapéutico de 4-6 ciclos y el 29.3% tuvieron respuesta objetiva. La tasa de supervivencia global (SG) fue de 22% a los 18 meses, con una mediana de supervivencia global (mSG) de 9 meses (CI 95%6,6 – 11,4) y fue estadísticamente superior en aquellos que recibieron de 4 -6 ciclos.
Conclusiones: En condiciones de la vida real la SG observada fue similar a la reportada internacionalmente. Este resultado puede servir como referencia a estudios futuros a conducir en nuestro medio.
Descargas
Citas
1. World Health Organization (WHO) Globocan, International Agency for Researc1 on Cancer (IARC) 2020 [acceso 3/1/2021]. Disponible en: http://globocan.iarc.fr
2. Anuario Estadístico de Salud 2021, Dirección de Registros Médicos y Estadísticas de Salud Ministerio de Salud Pública de Cuba. La Habana 2022; p 68 y 102. Visitado [20-02-2023] disponible en: https://files.sld.cu/dne/files/2022/10/Anuario-Estadistico-de-Salud-2021.-Ed-2022.pdf
3. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, et al. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2018 Feb;13(2):165-183. https://doi.org/10.1016/j.jtho.2017.11.111.
4. Vickers AD, Winfree KB, Carter GC, Kiiskinen U, Jen M, Stull D, et al. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis. BMC Cancer 2019; 19:353. https://doi.org/10.1186/s12885-019-5569-5.
5. Vergnenegre A, Monnet I, Bisieux A, Bernardi M, Chiapa AM, Léna H, et al. Open- label Phase II trial to evaluate safety and efficacy of second line metronomic oral vinorelvine – Atezolizumab combination for satge IV non-small cell lung cancer – VinMetAtezo trial, (GFPC‡ 04-2017). Future Oncol 2020; 16(4): 5-10. https://doi.org/10.2217/fon-2019-0730
6. Yuan C, Tao X, Zheng D, Pan Y, Ye T, Hu H, et al. The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer. J Surg Oncol 2019;119(3):379-387. https://doi.org/10.1002/jso.25308 .
7. Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol 2021; 18(9):547-557. https://doi.org/10.1038/s41571-021-00501-4.
8. Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Wang T, et al. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis. J Cell Physiol 2020;235(5):4913-4927. https://doi.org/10.1002/jcp.29371.
9. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc 2019;94(8):1623-1640. https://doi.org/10.1016/j.mayocp.2019.01.013 .
10. Hirsh V, Singh J. Optimal sequencing strategies in the treatment of EGFR mutation – positive non-small cell lung cancer: Clinical benefist and costo –effectivness. Am J Health Syst Pharm 2020; 77(18): 1466-1476. https://doi.org/10.1093/ajhp/zxaa197 .
11. Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okołów M, Dzięgiel P. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers (Basel) 2021;13(18):4705. https://doi.org/10.3390/cancers13184705 .
12. Singhi EK, Horn L, Sequist LV, Heymach J, Langer CJ. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. Am Soc Clin Oncol Educ Book 2019;39:e187-e197. https://doi.org/10.1200/EDBK_237821 .
13. Wu SG, Shih JY. Management of acquired resistence to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer 2018; 17(1):38. https://doi.org/10.1186/s12943-018-0777-1 .
14. Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev. 2022;1(1):CD013453. https://doi.org/10.1002/14651858.CD013453.pub2 .
15. Uras IZ, Moll HP, Casanova E. Targeting KRAS Mutant Non-Small Cell Lung Cancer: Past, Present and Future. Int J Mol Sci 2020; 21(12): 4325. https://doi.org/10.3390/ijms21124325 .
16. Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, et al. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019;14(6):1095-1101. https://doi.org/10.1016/j.jtho.2019.01.011 .
17. Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer 2020;20(1):1185. doi: 10.1186/s12885-020-07690-8.
18. Tang S, Qin C, Hu H, Liu T, He Y, Guo H, et al. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells 2022;11(3):320. https://doi.org/10.3390/cells11030320 .
19. Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res. 2019;25(15):4592-4602 https://doi.org/10.1158/1078-0432.CCR-18-1538.
20. Lazzari C, Bulotta A, Ducceschi M, Viganò MG, Brioschi E, Corti F, et al. Historical Evolution of Second Line Therapy in Non- Small Cell Lung Cancer. Front Med (Lausanne) 2017; 4:4. https://doi.org/10.3389/fmed.2017.00004.
21. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014 Feb;15(2):143-55. https://doi.org/10.1016/S1470-2045(13)70586-2.
22. Uprety D. Clinical utility of ramucirumab in non- small cell lung cancer. Biologics 2019; 13:133-137. https://doi.org/10.2147/BTT.S175034.
23. Davies J, Patel M, Gridelli C, de Marinis F, Waterkamp D, Mc Cusker ME. Real- world tratement patterns for patients receiving second-line treatment for advanced non-small cell lung cancer. A systematic review of recently published studies. PLoS One 2018; 12(4):e0175679. https://doi.org/10.1371/journal.pone.0175679.
24. Imai H, Kira K, Mori K, Kotake M, Mitani M, Kawashima N, et al. Post-progression survival is highly linked to overall survival in patients with non-small cell lung cancer harboring sensitive EGFR mutations treated with first-line epidemal growth factor receptor –tyrosine kinase inhibitors. Thorac Cancer 2019; 10(12): 2200-2208. https://doi.org/10.1111/1759-7714.13193.
25. Khozin S, Aberneti AP, Nassabum NC, Zhi J, Curtis MD, Tucker M, et al. Characteristic of Real – World Metastatic Non-Small Cell Lung Cancer patients Treated with Nivolumab and Pembrolizumab During The Year Following Approval. Oncologist 2018; 23(3): 328-336. https://doi.org/10.1634/theoncologist.2017-0353.
26. Armoiry X, Tsertsvadze A, Connock M, Royle P, Melendez-Torres GJ, Souquet PJ, et al Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis. PloS One 2018; 13(7): e19975. https://doi.org/10.1371/journal.pone.0199575.
27.Tiu AC, Potdar R, Djibo DA, Masab M, Dourado C. Clinical outcome of Afican American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community –based cancer center. Med Oncol 2018; 35(7): 109. https://doi.org/10.1007/s12032-018-1171-y.
28. Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, et al. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer Commun (Lond) 2022; 42(12):1314-1330. https://doi.org/10.1002/cac2.12385
29. Imai H, Yamaguchi O, Mori K, Hashimoto K, Akagami T, Sinomiya S, et al. Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. Thorac Cancer 2021; 12(8): 1171-2279. https://doi.org/10.1111/1759-7714.13886.
30. Fossella FV. Docetaxel in second-line treatment of non-small-cell lung cancer. Clin Lung Cancer. 2002 May;3 Suppl 2:S23-8. https://doi.org/10.3816/clc.2002.s.010.
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwart LH, Sargent D, Ford RR, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-47. https://doi.org/10.1016/j.ejca.2008.10.026.
32. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O´Rourke M, et al. Prospective Randomized trial of docetaxel versus Best supportive care in patients with non-small cell lung cancer previously treated with platinum – based chemotherpy. J Clin Oncol 2000; 18 (10): 2095- 103. https://doi.org/10.3816/clc.2002.s.010.
33. Camps C, Massuti B, Jimenez A, Maestu I, Gómez RG, Isla D, et al. Randomized phase III study of 3 –weekly versus weekly docetaxel in pretrated advanced non-small cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006; 17(3): 467-72. https://doi.org/10.1093/annonc/mdj115
34. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14(10):981-8. https://doi.org/10.1016/S1470-2045(13)70310-3.
35. Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014 Jun 20;32(18):1902-8. https://doi.org/10.1200/JCO.2013.52.4694.
36. Ma K, Cohen V, Kasymjanova G, Small D, Novac K, Peterson J et al. An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre. Curr Oncol. 2015 ;22(3):e157-63 https://doi.org/10.3747/co.22.2296.
37. Igawa S, Yokoba M, Takakura A, Hosotani S, Nakahara Y, Sato T, et al. Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease. Invest New Drugs. 2022 Feb;40(1):182-189. https://doi.org/10.1007/s10637-021-01162-x.
38. Herbst RS, Baas P, Kim DW, Felip E ,Pérez-García JL, Han JY et al, Pembrolizumab versus docetaxel for previously treated, PD-L1- positive, advanced non- small cell lung cancer (KEYNOTE 010): a randomised controlled trial. Lancet 2016; 387(10027):1540-1550. https://doi.org/10.1016/S0140-6736(15)01308-2.
39. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open –label, phase 2 reandomised controlled trial. Lancet 2016; 387 (10030): 1837-46. https://doi.org/10.1016/S0140-6736(16)00587-0
40. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treatednon-small cell lung cancer (OAK): a phase 3, open label, multicentre randomised controlled trial. Lancet 2017; 389 (10066): 255-265. https://doi.org/10.1016/S0140-6736(16)32517-X
41. Fehrenbacher L, von Pawe J, Park K, Rittmeyer Gandara DR, Ponce S, et al. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer. J Thorac Oncol 2018; 13 (8): 1156-1170. https://doi.org/10.1016/j.jtho.2018.04.039
42. Lu S, Wang J, Cheng Y, Mok T, ChangJ, Zhang L, et al. Nivolumab versus docetaxel in predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2- year follow –up from a randomized, open label, phase 3 study (ChecMate 078). Lung Cancer 2021; 152:7-14. https://doi.org/10.1016/j.lungcan.2020.11.013.
43. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland A, Han JY, et al. Atezolizumab treatment beyond progression in advanced NSCLC. Results from the ramdomized, Phase III OAK study. J Thorac Oncol 2018; 13(12): 1906-1918. https://doi.org/10.1016/j.jtho.2018.08.2027.
44. Borghaei H, Gettingger S, Vokes EE, Chow LQM, Burgio MA, de castro Capreno J, et al. Five Years outcomes from the randomized, Phase III Trials Chekmate 017 and 057: Nivolumab versus docetaxel in previously treated Non-small cell lung cancer. J Clin Oncol 2021; 39(10):1190. https://doi.org/10.1200/JCO.20.01605
45. Hanna N, Shepherd FA, Fossella FV, Pereira JR, Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22(9): 1589-97. https://doi.org/10.1200/JCO2004.08.163.
46. Huemer F, Lang D, Westphal T, Gampenrieder SP, Hutarew G, Weiss L, et al. Baseline Absolute Lynphocyte count and ECOG Performance Score are associated with Survival in advanced non-small cell lung cancer Undergoing PD-1/PD-L1 bolckade. J Clin Med 2019; 8(7): 1014. https://doi.org/10.3390/jcm8071014.
47. Herbst RS, Garón EB, Kim DW, Cho B, Gervais R, Pérez-García JL, et al. Five year survival update from KEYNOTE-010: Pembrolizumab vs Docetaxel for previously treated, programmed death –ligand 1- positive advanced NSCLC. J Thorac Oncol 2021; 16(10): 1718-1732. https://doi.org/10.1016/j.jtho.2021.05.001.
48. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379(21):2040-2051. https://doi.org/10.1056/NEJMOA1810865.
49. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018; 378: 2288–2301. https://doi.org/10.1056/NEJMOA1716948
50. Schuette W, Nagel S, Blankenburg T, Launtenschlaeger C, von Weikersthal LF, Dittrich I, et al. Phase III study of second line chemotherapy for advanced non small cell lung cancer with weekly compared with 3-´weekly docetaxel. J Clin Onco 2005; 23(33):8389-95. https://doi.org/10.1200/JCO.2005.02.3739.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.
Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.
El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.
